Promising predictors of checkpoint inhibitor response in NSCLC

References

• Howlader NNA, Krapcho M, Miller D, et al. SEER cancer statistics review, 1975–2014. Bethesda: National Cancer Institute; 2017 [cited 2020 Apr 10]. Available from: https://seercancergov/csr/1975_2014/
   Google Scholar
• Friedlaender A, Metro G, Signorelli D, et al. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab. Acta oncologica (Stockholm, Sweden). 2020;59(9).
   Web of Science ®Google Scholar
• Friedlaender A, Banna GL, Buffoni L, et al. Poor-performance status assessment of patients with non-small cell lung cancer remains vague and blurred in the immunotherapy era. Curr Oncol Rep. 2019;21:107.
   PubMed Web of Science ®Google Scholar
• Leighl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med. 2019;7:347–357.
   PubMed Web of Science ®Google Scholar
• Addeo A, Banna GL, Metro G, et al. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. Front Oncol. 2019;9:264.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez–Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J clin oncol. 2019;37:537–546.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–1830.
   PubMed Web of Science ®Google Scholar
• Spigel D Impower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. Barcelona, Spain: ESMO Congress; 2019 September 27-October 1. Abstract LBA78
   Google Scholar
• Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019;30:1653–1659.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Tiseo M, Banna GL, et al. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%. Cancer Immunol Immunother. 2020. DOI:10.1007/s00262-020-02613-9
   PubMed Web of Science ®Google Scholar
• Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12:208–222.
   PubMed Web of Science ®Google Scholar
• Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13:1302–1311.
   PubMed Web of Science ®Google Scholar
• McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer. JAMA Oncol. 2016;2:46–54.
   PubMed Web of Science ®Google Scholar
• Lee H-H, Wang Y-N, Xia W, et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell. 2019;36:168–78.e4. DOI:10.1016/j.ccell.2019.06.008
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon AE, Mhanna L, et al. Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). Journal of Clinical Oncology. 2018;36(15_suppl): 9010–9010. DOI:10.1200/JCO.2018.36.15_suppl.9010
   Google Scholar
• Friedlaender A, Drilon A, Weiss GJ, et al. KRAS as a druggable target in NSCLC: rising like a phoenix after decades of development failures. Cancer Treat Rev. 2020;85:101978.
   PubMed Web of Science ®Google Scholar
• Torralvo J, Friedlaender A, Achard V, et al. The activity of Immune Checkpoint Inhibition in KRAS mutated non-small cell lung cancer: a single centre experience. Cancer Genomics Proteomics. 2019;16:577–582.
   PubMed Web of Science ®Google Scholar
• Frisone D, Friedlaender A, Malapelle U, et al. A BRAF new world. Crit Rev Oncol Hematol. 2020;152:103008.
   PubMed Web of Science ®Google Scholar
• Friedlaender A, Drilon A, Banna GL, et al. The METeoric rise of MET in lung cancer. Cancer Cell. 2020. DOI:101002/cncr33159
   Google Scholar
• Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138–1145.
   PubMed Web of Science ®Google Scholar
• Friedlaender A, Banna G, Patel S, et al. Diagnosis and treatment of ALK aberrations in metastatic NSCLC. Curr Treat Options Oncol. 2019;20:79.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Byers LA, Diao L, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5:860–877.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822–835.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Schrock AB, Fabrizio D, et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. Am Soc Clin Oncol. 2016;34(15_suppl): 9017–9017. DOI:10.1200/JCO.2016.34.15_suppl.9017
   Web of Science ®Google Scholar
• Kowanetz M, Zou W, Shames D, et al. OA20. 01 tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients. J Thorac Oncol. 2017;12:S321–S2.
   Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–2104.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381:2020–2031.
   PubMed Web of Science ®Google Scholar
• Update on the phase III NEPTUNE trial of imfinzi plus tremelimumab in stage IV non-small cell lung cancer [press release]. AstraZeneca; Posted August 21 hb.
   Google Scholar
• Socinski M, Velcheti V, Mekhail T, et al. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Ann Oncol. 2019;30:v919–v20.
   Web of Science ®Google Scholar
• Friedlaender A, Nouspikel T, Christinat Y, et al. Tissue-Plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors. Front Oncol. 2020;10.
   PubMed Web of Science ®Google Scholar
• Addeo A, Banna GL, Weiss GJ. Tumor mutation burden—from hopes to doubts. JAMA Oncol. 2019;5(7):934–935. DOI:10.1001/jamaoncol.2019.0626
   PubMed Web of Science ®Google Scholar
• Bomze D, Ali OH, Bate A, et al. Association between immune-related adverse events during anti–PD-1 therapy and tumor mutational burden. JAMA Oncol. 2019;5:1633–1635.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12:738.
   PubMed Web of Science ®Google Scholar
• Prasad V, Addeo A. The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. Ann Oncol. 2020;31(9):1112–1114.
   Web of Science ®Google Scholar
• Subbiah V, Solit DB, Chan TA, et al. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Ann Oncol. 2020;31(9):1115–1118.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Le DT, Yoshino T, et al. KEYNOTE-177: phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC). J clin oncol. 2018;36:TPS877–TPS.
   Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:967–970.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359:91–97.
   PubMed Web of Science ®Google Scholar
• Jin Y, Dong H, Xia L, et al. The diversity of gut microbiome is associated with favorable responses to anti–programmed death 1 immunotherapy in chinese patients with NSCLC. J Thorac Oncol. 2019;14:1378–1389.
   PubMed Web of Science ®Google Scholar
• Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437–1444.
   PubMed Web of Science ®Google Scholar
• Tanoue T, Morita S, Plichta DR, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565:600–605.
   PubMed Web of Science ®Google Scholar
• Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Buti S, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019;7:57.
   PubMed Web of Science ®Google Scholar
• Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25:141–151.
   PubMed Web of Science ®Google Scholar
• Rassy EE, Ghosn M, Rassy NA, et al. Do immune checkpoint inhibitors perform identically in patients with weight extremes? Immunotherapy. 2018;10:733–736.
   PubMed Web of Science ®Google Scholar
• Maleki Vareki S, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017;116:116–124.
   PubMed Web of Science ®Google Scholar
• Mazzaschi G, Madeddu D, Falco A, et al. Low PD-1 expression in cytotoxic CD8(+) tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clinical cancer research: an official. J Am Assoc Cancer Res. 2018;24:407–419.
   PubMed Web of Science ®Google Scholar
• Uryvaev A, Passhak M, Hershkovits D, et al. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol. 2018;35:25.
   PubMed Web of Science ®Google Scholar
• Backman M, La Fleur L, Kurppa P, et al. Characterization of patterns of immune cell infiltration in NSCLC. J Thorac Oncol. 2020. DOI:10.1016/j.jtho.2019.12.127
   PubMedGoogle Scholar
• El-Hag A, Clark RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987;139:2406–2413.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI. 2014;106. DOI:10.1093/jnci/dju124
   Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Veneziani M, Buti S, et al. Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. Immunotherapy. 2018;10:681–694.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930–2940.
   PubMed Web of Science ®Google Scholar
• Hwang S, Kwon A-Y, Jeong J-Y, et al. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep. 2020;10:643.
   PubMed Web of Science ®Google Scholar
• Lee JS, Ruppin E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1. JAMA Oncol. 2019;5(11):1614.
   Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check point inhibitors. Anticancer Res. 2019;39:3961–3965.
   PubMed Web of Science ®Google Scholar
• Banna GL, Olivier T, Rundo F, et al. The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy. Front Med (Lausanne). 2019;6. DOI:10.3389/fmed.2019.00172
   PubMed Web of Science ®Google Scholar